This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Long-term exposure to arsenic in water may increase cardiovascular risk and especially heart disease risk even at exposure levels below the federal regulatory limit, according to new research. A study describes exposure-response relationships at concentrations below the current regulatory limit and substantiates that prolonged exposure to arsenic in water contributes to the development of ischemic heart disease.
(MedPage Today) -- Poor sleep at age 40 was associated with accelerated brain aging patterns at age 55, longitudinal data showed. A dose-response relationship emerged between the number of poor sleep characteristics early in midlife and brain.
In middle-aged people, having risk factors like blood pressure, blood sugar and cholesterol that are not well-controlled combined with not following certain healthy habits including exercise, diet and sleep, are linked to a higher risk of stroke, dementia or depression later in life, according to a new study. These results do not prove that not having healthy habits increases the risk of these conditions, they only show an association.
Healthgrades published its 2025 Specialty Excellence Awards recipients Oct. 22. Of those recipients, 50 hospitals were recognized for delivering superior clinical outcomes in cardiac surgery.
Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other conditions. The findings point to the possibility of developing such immunotherapies for heart failure in patients who have experienced a heart attack or other injury.
Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.
(MedPage Today) -- GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage of type 1 diabetes patients.
At AAO 2024, Kay describes encouraging interim safety and efficacy results from the ATSN-201 gene therapy trial in patients with X-linked retinoschisis.
98
98
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
At AAO 2024, Kay describes encouraging interim safety and efficacy results from the ATSN-201 gene therapy trial in patients with X-linked retinoschisis.
Many patients with pheochromocytoma and paraganglioma have hypertension from tumor-derived catecholamines. The HIF-2α inhibitor belzutifan rapidly reduced blood pressure and excess catecholamine levels.
A new study found that individuals with healthier cardiovascular systems are more likely to develop migraines, linking incident migraine to lower cardiovascular risk.
A study found people with schizophrenia have a 4-fold higher risk of sudden cardiac death compared to the general population, underscoring the need for cardiometabolic care.
At present, the clinical methods for preventing and treating contrast-induced nephropathy (CIN) are limited, and statins can play a better role during this process. So, we aimed to assess the atorvastatin on r.
The American Heart Association and American Stroke Association have updated the organizations' stroke prevention guidelines to include gender-focused insights and GLP-1 recommendations. The new guidelines were published Oct. 21 in Stroke.
West Orange, N.J.-based RWJBarnabas Health has appointed Conor Barrett, MD, senior vice president and chief clinical officer of heart and vascular services.
What is the impact of atrial fibrillation (AF) catheter ablation in patients with hypertrophic cardiomyopathy (HCM) on reduction in AF burden and symptoms?
What are the prognostic capabilities, calibration, and discrimination of the American Heart Association’s (AHA) Predicting Risk of Cardiovascular Disease Events (PREVENT) equations in a cohort representative of the US population when compared to the Pooled Cohort Equations (PCEs)?
Coronary artery calcification (CAC) is a common risk factor of cardiovascular disease. Although triglyceride glucose (TYG) index and high-density lipoprotein cholesterol (HDL-c) are both associated with CAC, n.
A Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021) equation was shown to.
Background We aimed to clarify the existence and pathological features of obesity cardiomyopathy (OCM) in Japan using our series of autopsy cases. Methods In this retrospective autopsy study, OCM was defined as cardiac hypertrophy (≥ 400 g in men, ≥ 320 g in women) of unknown aetiology in individuals with obesity (body mass index [BMI] ≥ 25 kg/m2 according to the Japanese definition of obesity).
Atrial fibrillation (AF) may have different clinical features in its early phase. Objective: This study compared the characteristics and clinical outcomes of early-phase AF with later-phase AF using a large multicenter prospective registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]).
Malignancy-related IBP has distinct features: shorter diagnosis time, higher ESR/CRP/LDH, lower hemoglobin, and often involves metastasis or paraneoplastic causes.
In regard to the Predicting Arrhythmic Event (PAT) score in Brugada syndrome patients derived from the Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) (1), the study presents important findings but a few points may benefit from further discussion and clarification.
Left bundle branch area pacing (LBBAP) results in a right bundle branch (RBB) delay pattern because of preexcitation of the left bundle. The mechanism of right ventricular (RV) activation during LBBAP is largely unknown.
Circulation, Ahead of Print. BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).
Practice guidelines recommend Ablation (ABL) in atrial fibrillation (AF) for rhythm control; guidance for antiarrhythmic drugs (AADs) post-ablation is limited.
Hypertension, Ahead of Print. BACKGROUND:Endothelial cell TRPV4 (transient receptor potential vanilloid 4) channels provide a control point that is pivotal in regulating blood vessel diameter by mediating the Ca2+-dependent release of endothelial-derived vasoactive factors. In hypertension, TRPV4-mediated control of vascular function is disrupted, but the underlying mechanisms and precise physiological consequences remain controversial.METHODS:Here, using a comprehensive array of methodologies,
Atrial leadless pacemaker(LP) is a novel device capable of atrial pacing and communicating with the ventricular LP to facilitate atrioventricular synchrony1. To better understand real-world safety data with atrial LP, we performed cross-sectional analysis of MAUDE (Manufacturer and User Facility Device Experience)-FDA mandated post-marketing safety surveillance database, which provides an unrestricted, deidentified medical device reports for the last 10 years.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content